"Phenylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the amino-N-phenylamide structure.
| Descriptor ID |
D010671
|
| MeSH Number(s) |
D02.455.426.559.389.703 D02.948.681
|
| Concept/Terms |
Phenylurea Compounds- Phenylurea Compounds
- Compounds, Phenylurea
- Phenylurea Derivatives
- Derivatives, Phenylurea
- Phenylcarbamides
|
Below are MeSH descriptors whose meaning is more general than "Phenylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Phenylurea Compounds".
This graph shows the total number of publications written about "Phenylurea Compounds" by people in this website by year, and whether "Phenylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 22 | 12 | 34 |
| 2018 | 14 | 4 | 18 |
| 2019 | 1 | 4 | 5 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Phenylurea Compounds" by people in Profiles.
-
Lenvatinib treatment for thyroid cancer in COVID era: safety in a patient with lung metastases and SARS-CoV-2 infection. Anticancer Drugs. 2021 11 01; 32(10):1116-1117.
-
Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir. J Gen Virol. 2021 07; 102(7).
-
Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data. Eur Rev Med Pharmacol Sci. 2021 04; 25(7):3122-3131.
-
How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. Clin Adv Hematol Oncol. 2020 Oct; 18 Suppl 16(10):1-24.
-
Third-line treatments for the management of metastatic colorectal cancer: why to change the mechanism of action after frontline chemotherapy, and insights into management during the COVID-19 pandemic. Clin Adv Hematol Oncol. 2020 10; 18 Suppl 16(10):6-14.
-
sEH Inhibitor Tppu Ameliorates Cecal Ligation and Puncture-Induced Sepsis by Regulating Macrophage Functions. Shock. 2020 06; 53(6):761-771.
-
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019 09; 4(9):721-730.
-
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019 09 01; 79(17):4326-4330.
-
RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. PLoS Pathog. 2019 03; 15(3):e1007601.
-
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncol. 2019 Mar; 15(9):929-941.